Notes
Amendments
24 June 2022 – Prevalence counts that are used in the calculation of spending per case of disease have been revised for some conditions in each of the following disease groups: infectious diseases, cardiovascular diseases and gastrointestinal diseases. In addition, benign and uncertain brain tumours, haemophilus influenzae type-b and all burden of disease conditions that contain ‘other’, ‘unknown’ or ‘uncertain’ in their description have all been excluded from the analysis due to the difficulty in obtaining reliable prevalence estimates for these conditions.
6 May 2022 – Prevalence counts that are used in the calculations for spending per case of disease for both hepatitis B and hepatitis C have been revised. The prevalence counts now include both acute and chronic cases for these two conditions. Previously the prevalence counts only included acute cases.